

# Propolis: Intrinsic Pathway-Induced Apoptosis, G1 Cell Cycle Arrest, Reduced Chemotherapeutic Resistance in Adenocarcinoma, and Healthy Cell Preservation

Nursel Isci<sup>1</sup> , Sibel Dogan<sup>1</sup> , Sahika Yardim<sup>1</sup> , Seyhun Solakoglu<sup>1</sup> , Ilhan Tahrali<sup>2</sup> , Gunnur Deniz<sup>2</sup> , Gulnaz Nural Bekiroglu<sup>3</sup> , Elif Kervancioglu Demirci<sup>1</sup> 

<sup>1</sup>Department of Histology and Embryology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkiye

<sup>2</sup>Department of Immunology, Aziz Sançar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkiye

<sup>3</sup>Department of Biostatistics, Faculty of Medicine, Marmara University, Istanbul, Turkiye

ORCID ID: N.I. 0000-0001-5134-3386; S.D. 0000-0002-3448-8070; S.Y. 0000-0002-5483-6896; S.S. 0000-0002-1389-9639; I.T. 0000-0001-9647-796X; G.D. 0000-0002-0721-6213; G.N.B. 0000-0001-6471-6612; E.K.D. 0000-0002-3158-9300

**Cite this article as:** Isci N, Dogan S, Yardim S, Solakoglu S, Tahrali I, Deniz G, Bekiroglu GN, Kervancioglu Demirci E. Propolis: Intrinsic pathway-induced apoptosis, G1 cell cycle arrest, reduced chemotherapeutic resistance in adenocarcinoma, and healthy cell preservation. *Experimed*. Advance Online Publication.

## ABSTRACT

**Objective:** This study investigated the potential synergistic effects of propolis, an antitumor and antioxidant natural product, and carboplatin, a frequently used chemotherapeutic agent for endometrial adenocarcinoma, one of the most common gynaecological cancers treatment.

**Materials and Methods:** Ishikawa endometrial adenocarcinoma and healthy fibroblast (3T3) cell lines were treated with 0.5  $\mu$ L of carboplatin and 5  $\mu$ L of propolis. Cell count, viability, migration, ultrastructure, apoptosis, and cell cycle changes were assessed using cytological and immunocytochemical methods, flow cytometry, and transmission electron microscopy (TEM).

**Results:** Propolis and carboplatin exhibited cytotoxic effects on Ishikawa cells. The combination of the two agents further reduced cell viability and migration. Propolis induced apoptosis through the intrinsic pathway and arrested the cell cycle in the G1 phase. TEM analysis revealed apoptosis in Ishikawa cells treated with propolis or carboplatin, while the carboplatin+propolis combination resulted in severe cell budding, apoptosis, and vacuolization. Migrasome-like structures were only observed in the Ishikawa carboplatin group. Minimal effects were observed on 3T3 cells.

**Conclusion:** Propolis demonstrated cytotoxic, anti-proliferative, and proapoptotic effects on tumor cells without harming healthy cells. Its ability to prevent migrasome formation suggests it may reduce chemotherapeutic resistance. Therefore, propolis shows promise as a potential enhancer of anticancer treatments.

**Keywords:** 3T3, apoptosis, electron microscopy, endometrium, Ishikawa, migrasome

## INTRODUCTION

Endometrial cancer is the most common cancer affecting women in both developed and developing countries worldwide, with the potential to cause infertility and even death in affected individuals (1-4). The Ishikawa endometrial epithelium continuous cell line, which expresses both estrogen

and progesterone receptors, is a widely used model to study endometrial adenocarcinoma, while the 3T3 fibroblast cell line was often employed as a control group in various *in vitro* studies (4, 5). The platinum group chemotherapeutic agent, carboplatin, is the preferred treatment option for endometrial cancer, with the aim of controlling the disease and increasing patient survival rates (6, 7).

**Corresponding Author:** Elif Kervancioglu Demirci **E-mail:** elifkervanciogلودemirci@istanbul.edu.tr

**Submitted:** 17.08.2023 **Revision Requested:** 09.10.2023 **Last Revision Received:** 18.10.2023 **Accepted:** 03.11.2023 **Published Online:** 04.12.2023



Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

There is promising evidence to suggest that combining carboplatin with herbal agents can improve cytotoxicity and increase survival rates in patients with endometrial cancer (8, 9). One such herbal supplement is propolis, a resinous substance collected by honeybees from plants, which has been shown to have anticarcinogenic, antioxidant, antifungal, and antibacterial effects, and have cytotoxic effect on various cancer cell lines (10-14). However, there is gap of research investigating the effects of propolis on endometrial cancer at a structural and ultrastructural level, and its mechanism of action remains poorly understood.

In this study, we aimed to investigate the potential of propolis extract to enhance the cytotoxic, apoptotic, and antitumor effects of carboplatin on the Ishikawa endometrial adenocarcinoma cell line, and to assess its effect on healthy 3T3 fibroblast cells. By elucidating the mechanism of action of propolis and carboplatin on both cancerous and healthy cells, we hope to improve the efficacy of cancer chemotherapy and contribute to the development of new treatment options for endometrial adenocarcinoma.

## MATERIALS AND METHODS

### Cell Culture

Ishikawa endometrial adenocarcinoma cell line derived from human endometrium (99040201, European Collection of Authenticated Cell Culture ECACC, Merck, Darmstadt, Germany), and 3T3 cell lines from mouse embryo fibroblast cells (86052701, European Collection of Authenticated Cell Culture ECACC, Merck, Darmstadt, Germany). Cell lines were cultured in 10% fetal bovine serum (FBS-11A, Capricorn, Germany), 100 µg/mL streptomycin, 100 IU/mL penicillin and 0.2 µM glutamine were filtered into sterile DMEM/F-12 (12500062, Thermo, Massachusetts, USA) medium. Cells were allowed to proliferate for 72 hours in a humidified incubator at 37°C containing 95% air and 5% CO<sub>2</sub>.

After conducting preliminary studies to determine the optimal propolis and carboplatin dosages at various time intervals according to the literature, a total of 8 experimental groups were established (15, 16). In these groups, propolis (5 µL) (Eğriçayır, İstanbul, Türkiye) and carboplatin (0.5 µL) (150 mg/15 mL) (Koçak Farma, Tekirdag, Türkiye) were administered individually and in combination (Table 1). All experiments were conducted in triplicate on Ishikawa cells and 3T3 cells, and each experiment was repeated three times.

| Group   | Treatment                     |
|---------|-------------------------------|
| Group 1 | Ishikawa Control              |
| Group 2 | Ishikawa+Propolis             |
| Group 3 | Ishikawa+Carboplatin          |
| Group 4 | Ishikawa+Propolis+Carboplatin |
| Group 5 | 3T3 Control                   |
| Group 6 | 3T3+Propolis                  |
| Group 7 | 3T3+Carboplatin               |
| Group 8 | 3T3+Propolis+Carboplatin      |

### Cell Viability Assay

1x10<sup>5</sup> numbers of Ishikawa and 3T3 cells were cultured in 12-well cell culture plates. The trypan blue test was performed to determine viability at 24 hours. Cell counts were conducted by using a Neubauer slide under the microscope (Olympus CKX41, Tokyo, Japan).

The viability ratio was calculated as follows: Viable cell ratio (%) = Count of unstained cells/Total number of cells x 100

### Measurement of Apoptosis in Cells by Flow Cytometry

The Annexin V-FITC Apoptosis Staining/Detection kit (Abcam-14085, Cambridge, Massachusetts, USA) was used to 1x10<sup>5</sup> Ishikawa and 3T3 cells following the manufacturer's recommended protocol. 5 µL of Annexin V-FITC and 5 µL of propidium iodide (PI) were added to 500 µL of Annexin V binding buffer, followed by a 5-minute incubation in the dark at room temperature. At the 24th hour, the apoptotic effect in the experimental groups were assessed using a flow cytometry device (NovoCyte, ACEA, BD Biosciences, New Jersey, USA).

### Cell Migration Assay

The migration of cells was monitored using the wound healing assay. A suspension of 2x10<sup>5</sup> cells/mL was prepared. Ishikawa and 3T3 cells were seeded in 6-well cell culture plates and allowed for 48 hours to adhere to the ground until they reached confluence. Subsequently, scratches were created with a pipette tip in the wells where the cells were seeded. The wells were then washed with medium to remove cell

**Table 2.** Effects of drugs on viability at 24th hour in Ishikawa and 3T3 cell lines.

| Viability % | Control     | Propolis     | Carboplatin | Propolis+Carboplatin | p-value |
|-------------|-------------|--------------|-------------|----------------------|---------|
| Ishikawa    | 96.23 ± 1.6 | 82.24 ± 6.5* | 83 ± 3.9*   | 81.53 ± 3.8*         | p<0.01  |
| 3T3         | 95.15 ± 0.7 | 95.30 ± 2.1  | 96.30 ± 1.6 | 95.79 ± 2.0          | p>0.05  |

Cell lines are compared with the control group; values were given as mean ± standard deviation; \*p<0.05.

debris, and fresh medium was added and dosed accordingly. The distance of the cells at specified points determined at 0 hours (initial), 24 hours and 48 hours were followed under the inverted microscope at 10x magnification and photographed. Results were measured with the Image J program.

Rate of cell migration was measured as follows:

$$\% \text{ of change} = - (\text{Initial wound width} - \text{Wound width at 24 hours}) / \text{Initial wound width} \times 100$$

$$\% \text{ of change} = - (\text{Initial wound width} - \text{Wound width at 48 hours}) / \text{Initial wound width} \times 100$$

### Immunocytochemistry

Cytochrome-c was examined to determine the effects of propolis and carboplatin on the intrinsic pathway of apoptosis. P27 showed the effects of propolis and carboplatin on the G1 phase of the cell cycle.

3x10<sup>4</sup> Ishikawa and 3T3 cells were seeded and kept in the incubator for 1 hour to adhere to the ground. 5 µL propolis and 0.5 µL carboplatin doses were applied to the cells and incubated for cytochrome-c staining for 24 hours and for p27 staining for 48 hours at 37°C with 5% CO<sub>2</sub>. Cells were fixed with 4% paraformaldehyde. They were then incubated in hydrogen

peroxide (H<sub>2</sub>O<sub>2</sub>) and block serum (TA-125-UB, Thermo Scientific, Massachusetts, USA).

For immunocytochemistry procedures, primary antibodies cytochrome-c (1:100, mouse anti-human, SC-13560, Santa Cruz, California, USA) and p27 (1:100, rabbit anti-human, SC-528, Santa Cruz, California, USA) were applied and incubated at +4°C overnight. A secondary antibody (Biotinylated Goat Anti-Polyvalent, Thermo Scientific, Massachusetts, USA) was applied for 1 hour and washed with PBS. After Streptavidin (TS-125-HR, Thermo Scientific, Massachusetts, USA) application, the cells were stained with AEC chromogen (TA-007-HAC, Thermo Scientific, Massachusetts, USA). Mayer's hematoxylin was used in cytochrome-c-stained preparations for counterstaining. Nuclear counterstaining was not done for p27 due to the staining localization of the primary antibody. At the end of the procedures, cells were sealed with an aqueous mounting medium (TA-125-AM, Thermo Scientific, Massachusetts, USA) and examined under a light microscope (Leica, DMLB, Wetzlar, Germany) and photographed. Two histologists unaware of the experimental groups counted ~400 cells, double-blind, and the mean of stained and unstained cell counts were noted in each preparation.

Staining was calculated as follows: Ratio of Stained Cells (%) = Stained cell count / Total counted cells x 100.

**Table 3.** Apoptosis rates of Ishikawa and 3T3 cell lines at 24th hour.

| Apoptotic Cell % | Control    | Propolis       | Carboplatin | Propolis+Carboplatin | p-value |
|------------------|------------|----------------|-------------|----------------------|---------|
| Ishikawa         | 5.68 ± 0.2 | 12.26 ± 0.4*** | 6.47 ± 0.2* | 12.04 ± 0.3***       | p<0.001 |
| 3T3              | 4.15 ± 0.4 | 3.61 ± 0.02    | 4.16 ± 0.05 | 3.69 ± 0.1           | p>0.05  |

Cell lines are compared with the control group; values were given as mean ± standard deviation; \*p<0.05, \*\*\*p<0.001.

**Table 4.** Migration rates of Ishikawa and 3T3 cell line at 24th and 48th hour.

| Cell Migration %   | Control n=30            | Propolis n=30             | Carboplatin n=30          | Propolis+Carboplatin n=30  | p-value |
|--------------------|-------------------------|---------------------------|---------------------------|----------------------------|---------|
| Ishikawa 24th hour | 75.27<br>(86.99, 33.34) | 54.95**<br>(77.04, 33.42) | 44.96**<br>(74.63, 10.16) | 38.06**<br>(56.76, 13.20)  | p<0.01  |
| Ishikawa 48th hour | 98.47<br>(99.68, 94.95) | 77.18**<br>(90.38, 50.80) | 80.51**<br>(95.52, 59.06) | 76.35**<br>(88.40, 60.65)  | p<0.01  |
| 3T3 24th hour      | 62.67<br>(82.39, 22.37) | 76.70*<br>(94.62, 33.03)  | 79.26*<br>(92.90, 53.52)  | 86.01***<br>(95.52, 35.39) | p<0.001 |
| 3T3 48th hour      | 86.11<br>(96.50, 64.11) | 95.48**<br>(98.40, 65.25) | 91.99<br>(96.19, 75.26)   | 96.63**<br>(98.77, 83.83)  | p<0.01  |

Cell lines are compared with the control group; values were given as median (max, min); \*p<0.05 \*\*p<0.01 \*\*\*p<0.001.

**Table 5.** Cytochrome-c ratios of Ishikawa and 3T3 cell lines at 24th hour.

| Cytochrome-c % | Control    | Propolis       | Carboplatin | Propolis+Carboplatin | p-value |
|----------------|------------|----------------|-------------|----------------------|---------|
| Ishikawa       | 5.67 ± 0.7 | 11.63 ± 0.8*** | 7.01 ± 0.3  | 13.34 ± 0.9***       | p<0.001 |
| 3T3            | 4.73 ± 0.1 | 3.91 ± 1.3     | 4.74 ± 1.2  | 4.00 ± 0.3           | p>0.05  |

Cell lines are compared with the control group; values were given as mean ± standard deviation; \*\*\*p<0.001.

**Table 6.** p27 ratios of Ishikawa and 3T3 cell lines at 48th hour.

| p27 %    | Control     | Propolis    | Carboplatin | Propolis+Carboplatin | p-value |
|----------|-------------|-------------|-------------|----------------------|---------|
| Ishikawa | 9.96 ± 3.5  | 16.30 ± 2.7 | 15.33 ± 3.7 | 22.15 ± 3.4**        | p<0.05  |
| 3T3      | 15.68 ± 4.0 | 15.15 ± 4.2 | 16.35 ± 1.6 | 16.80 ± 0.7          | p>0.05  |


Cell lines are compared with the control group; values were given as mean ± standard deviation; \*\*p<0.01.

### Investigation of Ultrastructural Changes in Cells by Transmission Electron Microscopy (TEM)


5x10<sup>5</sup> live cells from each group were used for the TEM examination. The samples collected at the 24th hour from the experimental groups were prepared for investigation. Cells were fixed in 2.5% glutaraldehyde (104239, Merck, Darmstadt, Germany) solution for primary fixation and 1% osmic acid (124505.0100, Merck, Darmstadt, Germany) in PBS for secondary fixation. Cells were washed with PBS in between the steps. A graded series of alcohol were used for dehydration. After the propylene oxide/epon mixtures, cells were embedded in epon (45359-1EA-F, Epon 812, Sigma, Missouri, USA) and polymerized for 18 hours at 60°C. Thin sections of 60 nm were taken with an ultramicrotome (EM UC7, Leica, Wetzlar, Germany) to pyeloform-coated copper grids. Contrast was performed with uranyl acetate and lead citrate. Three histologists evaluated the specimens using TEM (JEM 1011, JEOL, Tokyo, Japan).

### Statistical Analyses


The statistical analyses of the study were conducted using GraphPad Prism 9.2.0 (GraphPad Software, San Diego, California, USA) program and MS-Excel 2013. Normal distribution was assessed using the Kolmogorov-Smirnov and Shapiro-Wilk tests for all data. For normally distributed groups, one-way ANOVA test and post-hoc Tukey tests were employed, while Kruskal-Wallis and post-hoc Dunn's tests were used for groups that did not exhibit normal distribution. Evaluations between Ishikawa and 3T3 groups were performed using Student's t-test and Mann-Whitney U test. A significance level of p<0.05 was considered statistically significant. The results presented in the tables included mean ± standard deviation for normally distributed groups and median, R (max, min) for non-normally distributed groups. The average of three replicates was taken for the study. Changes in wound width during migration experiments were calculated using the percentage change



**Figure 1.** Comparison of Ishikawa and 3T3 cell line A) viability and B) apoptosis at 24 hours between groups. Data was expressed as mean and standard deviation, \*\*\*p<0.001, \*\*p<0.01, \*p<0.05.



**Figure 2.** Phase contrast micrographs of cell migration assays at 0, 24 and 48 hours A) Ishikawa cell line. Single treatments of propolis or carboplatin reduce migration and most significant migration deteriorating effect was observed in the propolis+carboplatin group. B) 3T3 cell line. There were no difference in cell migration in the 3T3 cell line experimental groups compared to the control group. C) 24 and D) 48-hour migration rates. 10x magnification. Bar: 100  $\mu$ m; \*\* $p < 0.01$



**Figure 3.** Cytochrome-c immunohistochemistry of A, B, C, D Ishikawa cells and E, F, G, H 3T3 cells at 24 hours. Cytoplasmic cytochrome-c positive cells with red cytoplasm (arrow) and cytochrome-c negative (arrowhead) cells are seen in all groups in different counts. Nuclei was counterstained with hematoxylin (blue) in all cells. I. Cytochrome-c ratios show the comparison of stained cell counts. While cytochrome-c staining was observed in all groups of Ishikawa cells, it was noted that the stained cell count was more in the propolis+carboplatin group. There was no difference in 3T3 cells cytochrome-c staining in experimental groups. The difference between Ishikawa and 3T3 is most profound in propolis+carboplatin groups. 40x magnification. Bar: 100  $\mu$ m; \*\*\* $p$ <0.001, \* $p$ <0.05.

formula. Apoptosis data were analyzed using NovoExpress software.

## RESULTS

### The Exposure of Propolis for 24h Decreased Cell Viability of Ishikawa Cells


The viability of the Ishikawa experimental groups were statistically different from each other ( $p=0.0086$ ). A pairwise comparison of experimental groups with the control group showed a significant decrease in propolis ( $p=0.0169$ ), carboplatin ( $p=0.0226$ ) and propolis+carboplatin ( $p=0.0129$ ). There was no difference in viability between 3T3 cell groups (Table 2).

groups ( $p=0.0292$ ), carboplatin groups ( $p=0.0054$ ), and propolis+carboplatin groups ( $p=0.0044$ ). Carboplatin and/or propolis decreased the viability of Ishikawa cells (Figure 1A).

### The Exposure of Propolis for 24h Increased Apoptosis of Ishikawa Cells

Propolis ( $p=0.0002$ ), carboplatin ( $p=0.0385$ ), and propolis+carboplatin groups ( $p=0.0003$ ) had increased apoptosis in Ishikawa cells compared to the control group. There was no difference in the apoptosis rates in experimental groups of 3T3 cells (Table 3).

When apoptosis values of the two cell lines were compared with each other, the difference was significant between control groups ( $p=0.0044$ ), propolis groups ( $p=0.0002$ ), carboplatin groups ( $p=0.0005$ ), and propolis+carboplatin groups ( $p=0.0003$ ), and apoptosis was increased in the Ishikawa cell line (Figure 1B).



**Figure 4.** P27 Immunohistochemistry of A, B, C, D Ishikawa cells and E, F, G, H 3T3 cells at 48 hours. The p27 staining (red) intensity of Ishikawa cells was higher in treatment groups than in the control group with the most intense staining in the propolis+carboplatin group. P27 staining of 3T3 cells does not differ between groups. Nuclei of p27 positive (arrow) and p27 negative (arrowhead) cells are seen. 40x magnification. Scale bar: 100  $\mu$ m.

### Propolis Increased Migration in 3T3 Cells and Decreased Migration in Ishikawa Cells

Cell migration assay showed a statistically significant difference between groups of Ishikawa cells at 24 hours ( $p < 0.01$ ) and 48 hours ( $p < 0.01$ ). Carboplatin and/or propolis decreased the rate of migration of Ishikawa cells. The migration of Ishikawa cells at the 24th hour in propolis ( $p = 0.0035$ ), carboplatin ( $p = 0.0023$ ), and propolis+carboplatin ( $p = 0.0015$ ) experimental groups were lower when compared with the control group. The migration of Ishikawa cells at the 48th hour in propolis ( $p = 0.0029$ ), carboplatin ( $p = 0.0019$ ) and, propolis+carboplatin ( $p = 0.0011$ ) experimental groups were also lower than the control group.

The differences in migration between groups of 3T3 cells were significant at 24 hours ( $p < 0.001$ ) and 48 hours ( $p < 0.01$ ). However, propolis increased the rate of migration in 3T3 cells. The migration of 3T3 cells at 24th hours was increased in propolis ( $p = 0.0243$ ), carboplatin ( $p = 0.0188$ ) and propolis+carboplatin ( $p = 0.0002$ ) experimental groups than in the control group. The migration rate of 3T3 cells was increased in the propolis ( $p = 0.0031$ ), and propolis+carboplatin ( $p = 0.0018$ ) experimental groups at 48 hours (Table 4).

The difference between the same groups of Ishikawa and 3T3 cell lines was significant at 24 hours, and the migration in the Ishikawa cell line was lower in the propolis groups ( $p = 0.0062$ ), carboplatin groups ( $p = 0.0032$ ) and propolis+carboplatin groups ( $p = 0.0015$ ). The migration of the control groups at 24 hours was different, and it was lower in the 3T3 cell line ( $p = 0.0073$ ). At the 48th hour, migration was less in the Ishikawa cell line and the difference was significant between propolis groups ( $p = 0.0023$ ), carboplatin groups ( $p = 0.0015$ ) and propolis+carboplatin groups ( $p = 0.0011$ ). The difference was

significant between the control groups at 48 hours, and the migration was lower in the 3T3 cell line ( $p = 0.0031$ , Figure 2).

### Propolis Increased Cytochrome C in Ishikawa Cells

The cytochrome c ratio of Ishikawa cells was statistically different ( $p < 0.001$ ). The propolis ( $p = 0.0006$ ) and propolis+carboplatin ( $p = 0.0002$ ) experimental groups exhibited a higher cytochrome c ratio compared to the control group. However, there was no significant difference in the cytochrome c ratio among the experimental groups of 3T3 cells (Table 5, Figures 3A-H).

Significant differences were observed between the Ishikawa and 3T3 cell lines in the same experimental groups. The cytochrome c levels in the propolis groups ( $p = 0.0006$ ), carboplatin groups ( $p = 0.0323$ ), and propolis+carboplatin ( $p = 0.0002$ ) were higher in the Ishikawa cell line. No significant difference was found between the control groups (Figure 3I).

### Propolis+carboplatin Exposure Increased p27 in Ishikawa Cells

Comparing all groups, the p27 ratio of Ishikawa cells showed statistical differences ( $p = 0.0146$ ). Pairwise comparison indicated a significant difference only between the control and propolis+carboplatin experimental groups ( $p = 0.0093$ ). However, there was no significant difference in the p27 ratio of 3T3 cells (Table 6, Figures 4A-H).

The p27 ratio between the groups of Ishikawa and 3T3 cell lines groups displayed relative, but not statistically significant differences in the propolis groups ( $p = 0.7079$ ) and propolis+carboplatin ( $p = 0.0563$ ).



## DISCUSSION

In our study, we investigated the effect of propolis on endometrial adenocarcinoma using cell culture techniques in combination with carboplatin, a chemotherapeutic agent commonly used in standard treatment.

Carboplatin exerts a cytotoxic effect by inhibiting cell proliferation of endometrial cancer cells (17). It increases cytochrome c release in the cytoplasm of human ovarian cancer cells and induces apoptosis in cervical carcinoma cells (18, 19). Additionally, it has an antimetastatic effect on the laryngeal carcinoma cell line (20). In our study, carboplatin increased the rate of apoptosis, reduced cell migration, and relatively elevated the rate of cytochrome c in Ishikawa cells. Since cytochrome c is associated with the intrinsic pathway of apoptosis, our study suggests that carboplatin is effective in triggering this intrinsic pathway. Although carboplatin is theoretically assumed to act on the S phase, it is not specific to the cell cycle. As an alkylating antineoplastic agent, it forms reactive platinum complexes within DNA molecule chains in the cell, leading to changes in DNA structure and inhibition of DNA synthesis. This can impact the cell cycle in every phase (21-23). Our results regarding the effect of carboplatin were consistent with the existing literature. TEM showed cell budding, increased vacuolization, the presence of apoptotic bodies, loss of microvilli, condensation of nuclei, the presence of migrasome-like structures, and organelle degeneration. These effects were minimal in the 3T3 cell line, which consists of healthy cells.

Migrasomes are classified as extracellular vesicles that mediate intercellular communication by removing unwanted molecules from cells and transferring cargo molecules to other recipient cells. Recently, migrasomes have been used to prevent resistance to cancer drugs (24-26). Our study is a first in the literature reporting that carboplatin-caused migrasome-like structure formation of Ishikawa cells is not produced in propolis treatment. The reason why migrasome structures were found only in the carboplatin experimental group of Ishikawa cells may be that tumor cells are resistant to the chemotherapeutic agent and are expelled from the cell, filopod structures are more uniform and more in number than other experimental groups, and the migration rate is high. In addition, no migrasome-like structures were found in the Ishikawa cells propolis+carboplatin treatment group, which suggested that propolis might play a role in a possible mechanism preventing the excretion of the chemotherapeutic agent carboplatin by tumor cells. However, the migrasomes observed and confirmed by three histologists with TEM were not verified by another method.

Propolis and its phenolic compounds can serve as a strong adjunct to radiotherapy and chemotherapy (27, 28). It has no known severe, moderate, or mild interactions with other drugs. Propolis decreases viability in MCF-7 and MDA-MB-231 breast cancer cell lines in a dose- and time-dependent manner but has no such effect on HUVEC cells (29). In our study, we found

that propolis had a cytotoxic effect by reducing the viability of Ishikawa cells. It also had no such effect on 3T3 cells. Propolis inhibits the cell cycle in G0/G1 in human gastric cancer cells and in the G1 phase in human breast cancer cells (30, 31). As a result of our study, there was a relative increase in the p27 ratio in Ishikawa cells, which was not statistically significant. This suggested that different doses of propolis could be tested to arrest the cell cycle in the G1 phase, in line with the literature.

Propolis provides the mechanism of apoptosis both by stimulating the caspase cascade (intrinsic pathway) through the release of cytochrome-c from the mitochondria to the cytosol and by stimulating the TRAIL signalling pathway (extrinsic pathway) (32, 33). It has an apoptotic effect on the human leukemia cancer cell line U937 (34). The effect of propolis on human leukemia HL-60 cells involves the release of cytochrome-c from the mitochondria to the cytoplasm, stimulating the mitochondrial pathway, reducing cancer cell proliferation, and inducing apoptosis (35). We demonstrated that propolis induces apoptosis in the Ishikawa cell line through flow cytometry and confirmed that this occurs via the intrinsic pathway using our cytochrome-c immunocytochemical staining results. In Ishikawa cells treated with propolis; we observed increased cell budding, apoptotic bodies and vacuoles in TEM examinations, indicating the apoptotic effect of propolis. However, we did not observe apoptotic effects of propolis in 3T3 cell line experimental groups. Therefore, we concluded that propolis, which affects cancer cells, does not induce apoptosis in fibroblast cells.

Propolis inhibits cell migration in a dose-dependent manner at 48 hours on breast cancer cells. Supplements to anticancer treatments were studied in order to prevent metastasis. In this study, we investigated the metastatic activity of cancer cells using the migration test in accordance with the literature (29). Propolis slowed down cell migration of Ishikawa cells significantly when compared with the control group. Propolis was effective against metastasis.

The strengths of this study include the use of *in vitro* methods to investigate the effects of propolis and carboplatin on cancerous and healthy cells, with dosages selected based on relevant literature and preliminary studies. Another advantage is the observation of ultrastructural effects on cells without interference from *in vivo* conditions. However, a limitation is the need for further *in vivo* studies to determine the therapeutic dose for humans. Additionally, it should be noted that the composition of endemic propolis may vary geographically, which could impact its efficacy and safety in different regions. For future studies on chemotherapy resistance, a resistant cell line can be utilized, and a combination index analysis can be conducted to assess the efficacy of propolis and carboplatin in combination (36, 37).

Propolis combined with carboplatin has stronger cytotoxic and apoptotic effects on Ishikawa cells. Additionally, we observed the possibility of inhibiting treatment resistance.

This combination treatment resulted in severe apoptotic consequences for Ishikawa cells, including an increase in vacuole size and number, cell budding, apoptotic bodies, condensed relocated nuclei, a decrease in the number of microvilli, reduced cell sizes with degenerations in cytoplasmic organelles, and an increased number of advanced apoptotic degenerative cells. Our results showed that propolis and carboplatin have synergistic effects. They increased apoptosis via the intrinsic pathway and blocked the cell cycle in the G1 phase. In our examinations, we did not observe any finding suggesting any cytotoxic effect on 3T3 cells when propolis and carboplatin were administered together. In the literature, propolis did not cause cytotoxic effects in human dermal fibroblast cells; however, it increases viability, cell migration and migration rate. Hence, the increase in the migration rate of the 3T3 propolis and combination group in our study was suggested as the positive reported effect of propolis on wound healing (38). Other mechanisms of propolis on cancer cells are still under study (39).

In conclusion, propolis has demonstrated its synergistic effects with carboplatin on the endometrial cancer cell line, with no moderate or severe effects on fibroblast cells. These findings regarding the potential benefits of propolis as a dietary supplement suggest that it could be incorporated into the treatment regimens to enhance the prognosis and success of cancer chemotherapy for endometrial adenocarcinoma. Furthermore, it may warrant further investigation as a complementary approach in other chemotherapeutic studies.

**Ethics Committee Approval:** This research includes commercial cell lines Ishikawa and 3T3. An ethical approval is not needed because human or animal subjects or primary cell culture from human or animal subjects are not involved.

**Peer-review:** Externally peer-reviewed.

**Authors' Contributions:** Conception/Design of Study- N.I., S.S., E.K.D.; Data Acquisition: N.I., S.D., I.T., G.D., S.S., E.K.D.; Data Analysis/ Interpretation: N.I., S.S., G.N.B., E.K.D., S.Y.; Drafting Manuscript: N.I., S.Y., E.K.D.; Critical Revision of Manuscript: S.D., I.T., G.D., G.N.B., S.S.; Final Approval and Accountability N.I., S.D., S.Y., I.T., G.D., G.N.B., S.S., E.K.D.

**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** This study was funded by Scientific Research Projects Coordination Unit of Istanbul University (Project No: 37221).

## REFERENCES

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; 61(2): 69-90.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016; 66(1): 7-30.
3. Crissman JD, Azoury RS, Barnes AE, Schellhas HF. Endometrial carcinoma in women 40 years of age or younger. *Obstet Gynecol* 1981; 57(6): 699-704.

4. Nishida M. The Ishikawa cells from birth to the present. *Hum Cell* 2002; 15(3): 104-17.
5. Woodford-Thomas TA, Rhodes JD, Dixon JE. Expression of a protein tyrosine phosphatase in normal and v-src-transformed mouse 3T3 fibroblasts. *J Cell Biol* 1992; 117(2): 401-14.
6. Zagouri F, Bozas G, Kafantari E, Tsiatas M, Nikitas N, Dimopoulos MA, et al. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? *Obstet Gynecol Int* 2010; 2010: 749579.
7. Kumar A, Sirohi VK, Anum F, Singh PK, Gupta K, Gupta D, et al. Enhanced apoptosis, survivin down-regulation and assisted immunochemotherapy by curcumin-loaded amphiphilic mixed micelles for subjugating endometrial cancer. *Nanomedicine* 2017; 13(6): 1953-63.
8. SGO Clinical Practice Endometrial Cancer Working Group; Burke WM, Orr J, Leitaó M, Salom E, Gehrig P, et al. Endometrial cancer: a review and current management strategies: part II. *Gynecol Oncol* 2014; 134(2): 393-402.
9. Jia N, Che X, Jiang Y, Zhu M, Yang T, Feng W. Synergistic effects of a combined treatment of PI3K/mTOR dual inhibitor LY3023414 and carboplatin on human endometrial carcinoma. *Gynecol Oncol* 2021; 162(3): 788-96.
10. Castaldo S, Capasso F. Propolis, an old remedy used in modern medicine. *Fitoterapia* 2002; 73 Suppl 1: S1-6.
11. Burdock GA. Review of the biological properties and toxicity of bee propolis (propolis). *Food Chem Toxicol* 1998; 36(4): 347-63.
12. Viuda Martos M, Ruiz Navajas Y, Fernández López J, Pérez Álvarez JA. Functional properties of honey, propolis, and royal jelly. *J Food Sci* 2008; 73(9): R117-24.
13. Turan I, Demir S, Misir S, Kilinc K, Mentese A, Aliyazicioglu Y, et al. Cytotoxic effect of Turkish propolis on liver, colon, breast, cervix and prostate cancer cell lines. *Trop J Pharm Res* 2015; 14(5): 777-82.
14. Demir S, Aliyazicioglu Y, Turan I, Misir S, Mentese A, Yaman SO, et al. Antiproliferative and proapoptotic activity of Turkish propolis on human lung cancer cell line. *Nutr Cancer* 2016; 68(1): 165-72.
15. Kubina R, Kabala-Dzik A, Dziedzic A, Bielec B, Wojtyczka RD, Buldak RJ, et al. The ethanol extract of Polish propolis exhibits anti-proliferative and/or pro-apoptotic effect on HCT 116 colon cancer and Me45 malignant melanoma cells in vitro conditions. *Adv Clin Exp Med* 2015; 24(2): 203-12.
16. Rantanen V, Grenman S, Kulmala J, Grenman R. Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines. *Br J Cancer* 1994; 69(3): 482-6.
17. Kuitinen T, Rovio P, Staff S, Luukkaala T, Kallioniemi A, Grenman S, et al. Paclitaxel, carboplatin and 1,25-D3 inhibit proliferation of endometrial cancer cells in vitro. *Anticancer Res* 2017; 37(12): 6575-81.
18. Lee CS, Kim YJ, Jang ER, Myung SC, Kim W. Akt inhibitor enhances apoptotic effect of carboplatin on human epithelial ovarian carcinoma cell lines. *Eur J Pharmacol* 2010; 632(1-3): 7-13.
19. Singh S, Upadhyay AK, Ajay AK, Bhat MK. p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: a novel target of p53 in apoptosis. *FEBS Lett* 2007; 581(2): 289-95.
20. He PJ, Ge RF, Mao WJ, Chung PS, Ahn JC, Wu HT. Oxidative stress induced by carboplatin promotes apoptosis and inhibits migration of HN-3 cells. *Oncol Lett* 2018; 16(6): 7131-8.
21. Coleman SC, Stewart ZA, Day TA, Netterville JL, Burkey BB, Pietenpol JA. Analysis of cell-cycle checkpoint pathways in head and neck cancer cell lines: implications for therapeutic strategies. *Arch Otolaryngol Head Neck Surg* 2002; 128(2): 167-76.

22. Kelland L. The resurgence of platinum-based cancer chemotherapy. *Nat Rev Cancer* 2007; 7(8): 573-84.
23. Sousa GFd, Wlodarczyk SR, Monteiro G. Carboplatin: molecular mechanisms of action associated with chemoresistance. *Brazilian J Pharma Sci* 2014; 50: 693-701.
24. Eguchi T, Taha EA, Calderwood SK, Ono K. A novel model of cancer drug resistance: oncosomal release of cytotoxic and antibody-based drugs. *Biology (Basel)* 2020; 9(3): 47.
25. Eguchi T, Ono K, Calderwood S, Okamoto K. Exosome release of drugs: coupling with epithelial-mesenchymal transition. *Preprints* 2019; 2019120386. doi:10.20944/preprints201912.0386.v1
26. Zhao X, Wu X, Qian M, Song Y, Wu D, Zhang W. Knockdown of TGF-beta1 expression in human umbilical cord mesenchymal stem cells reverts their exosome-mediated EMT promoting effect on lung cancer cells. *Cancer Lett* 2018; 428: 34-44.
27. Orsolic N, Knezevic AH, Sver L, Terzic S, Basic I. Immunomodulatory and antimetastatic action of propolis and related polyphenolic compounds. *J Ethnopharmacol* 2004; 94(2-3): 307-15.
28. Lamoral-Theys D, Pottier L, Dufrasne F, Nève J, Dubois J, Kornienko A, et al. Natural polyphenols that display anticancer properties through inhibition of kinase activity. *Curr Med Chem* 2010; 17(9):812- 25.
29. Xuan H, Li Z, Yan H, Sang Q, Wang K, He Q, et al. Antitumor activity of Chinese propolis in human breast cancer MCF-7 and MDA-MB-231 cells. *Evid Based Complement Alternat Med* 2014; 2014: 280120.
30. Desamero MJ, Kakuta S, Tang Y, Chambers JK, Uchida K, Estacio MA, et al. Tumor-suppressing potential of stingless bee propolis in in vitro and in vivo models of differentiated-type gastric adenocarcinoma. *Sci Rep* 2019; 9(1): 19635.
31. Misir S, Aliyazicioglu Y, Demir S, Turan I, Hepokur C. Effect of Turkish propolis on miRNA expression, cell cycle, and apoptosis in human breast cancer (MCF-7) cells. *Nutr Cancer* 2020; 72(1): 133-45.
32. Szliszka E, Czuba ZP, Domino M, Mazur B, Zydowicz G, Krol W. Ethanolic extract of propolis (EEP) enhances the apoptosis-inducing potential of TRAIL in cancer cells. *Molecules* 2009; 14(2): 738-54.
33. Sawicka D, Car H, Borawska MH, Niklinski J. The anticancer activity of propolis. *Folia Histochem Cytobiol* 2012; 50(1): 25-37.
34. Motomura M, Kwon KM, Suh SJ, Lee YC, Kim YK, Lee IS, et al. Propolis induces cell cycle arrest and apoptosis in human leukemic U937 cells through Bcl-2/Bax regulation. *Environ Toxicol Pharmacol* 2008; 26(1): 61-7.
35. Eom HS, Lee EJ, Yoon BS, Yoo BS. Propolis inhibits the proliferation of human leukaemia HL-60 cells by inducing apoptosis through the mitochondrial pathway. *Nat Prod Res* 2010; 24(4): 375-86.
36. Viscarra T, Buchegger K, Jofre I, Riquelme I, Zanella L, Abanto M, et al. Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line. *Biol Res* 2019; 52(1): 1-13.
37. Castañeda AM, Meléndez CM, Uribe D, Pedroza-Díaz J. Synergistic effects of natural compounds and conventional chemotherapeutic agents: Recent insights for the development of cancer treatment strategies. *Heliyon* 2022; 8(6): e09519.
38. Ebadi P, Fazeli M. Evaluation of the potential in vitro effects of propolis and honey on wound healing in human dermal fibroblast cells. *South African J Botany* 2021; 137: 414-22.
39. Altabbal S, Athamnah K, Rahma A, Wali AF, Eid AH, Itratni R, et al. Propolis: a detailed insight of its anticancer molecular mechanisms. *Pharmaceuticals* 2023; 16(3), 450.